Literature DB >> 21153517

The substrates of Plk1, beyond the functions in mitosis.

X Shawn Liu1, Bing Song, Xiaoqi Liu.   

Abstract

Polo-like kinase 1 (Plk1) is a key regulator of cell division in eukaryotic cells. In this short review, we briefly summarized the well-established functions modulated by Plk1 during mitosis. Beyond mitosis, we focused mainly on the unexpected processes in which Plk1 emerges as a critical player, including microtubule dynamics, DNA replication, chromosome dynamics, p53 regulation, and recovery from the G2 DNA-damage checkpoint. Our discussion is mainly based on the critical substrates targeted by Plk1 during these cellular events and the functional significance associated with each phosphorylation event.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153517      PMCID: PMC4875153          DOI: 10.1007/s13238-010-0131-x

Source DB:  PubMed          Journal:  Protein Cell        ISSN: 1674-800X            Impact factor:   14.870


  100 in total

1.  TIN2, a new regulator of telomere length in human cells.

Authors:  S H Kim; P Kaminker; J Campisi
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

2.  Identification of a novel gene encoding a p53-associated protein.

Authors:  R Zhou; H Wen; S Z Ao
Journal:  Gene       Date:  1999-07-22       Impact factor: 3.688

3.  MRE11-RAD50-NBS1 and ATM function as co-mediators of TRF1 in telomere length control.

Authors:  Yili Wu; Shujie Xiao; Xu-Dong Zhu
Journal:  Nat Struct Mol Biol       Date:  2007-08-12       Impact factor: 15.369

4.  Polo kinase and separase regulate the mitotic licensing of centriole duplication in human cells.

Authors:  Meng-Fu Bryan Tsou; Won-Jing Wang; Kelly A George; Kunihiro Uryu; Tim Stearns; Prasad V Jallepalli
Journal:  Dev Cell       Date:  2009-09       Impact factor: 12.270

5.  Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery.

Authors:  X Shawn Liu; Hongchang Li; Bing Song; Xiaoqi Liu
Journal:  EMBO Rep       Date:  2010-06-25       Impact factor: 8.807

6.  Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck.

Authors:  R Knecht; R Elez; M Oechler; C Solbach; C von Ilberg; K Strebhardt
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

7.  topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage.

Authors:  Ling Lin; Toshinori Ozaki; Yuki Takada; Hajime Kageyama; Yoko Nakamura; Akira Hata; Jian-Hua Zhang; William F Simonds; Akira Nakagawara; Haruhiko Koseki
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

8.  Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo.

Authors:  Stefan Weger; Eva Hammer; Regine Heilbronn
Journal:  FEBS Lett       Date:  2005-09-12       Impact factor: 4.124

Review 9.  Polo-like kinases and oncogenesis.

Authors:  Frank Eckerdt; Juping Yuan; Klaus Strebhardt
Journal:  Oncogene       Date:  2005-01-10       Impact factor: 9.867

10.  Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53.

Authors:  Rajeev Rajendra; Diptee Malegaonkar; Pooja Pungaliya; Henderson Marshall; Zeshaan Rasheed; James Brownell; Leroy F Liu; Stuart Lutzker; Ahamed Saleem; Eric H Rubin
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

View more
  24 in total

1.  Chemical visualization of phosphoproteomes on membrane.

Authors:  Anton Iliuk; X Shawn Liu; Liang Xue; Xiaoqi Liu; W Andy Tao
Journal:  Mol Cell Proteomics       Date:  2012-05-16       Impact factor: 5.911

Review 2.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

3.  Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).

Authors:  Zhiguo Li; Ying Lu; Nihal Ahmad; Klaus Strebhardt; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 4.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

5.  SUMOylation Promotes Nuclear Import and Stabilization of Polo-like Kinase 1 to Support Its Mitotic Function.

Authors:  Donghua Wen; Jianguo Wu; Lei Wang; Zheng Fu
Journal:  Cell Rep       Date:  2017-11-21       Impact factor: 9.423

6.  Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.

Authors:  Jie Li; Ruixin Wang; Patrick G Schweickert; Anju Karki; Yi Yang; Yifan Kong; Nihal Ahmad; Stephen F Konieczny; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

7.  Clathrin heavy chain phosphorylated at T606 plays a role in proper cell division.

Authors:  Yusuke Yabuno; Toshihiro Uchihashi; Towa Sasakura; Hiroyuki Shimizu; Yoko Naito; Kohshiro Fukushima; Kaori Ota; Mikihiko Kogo; Hiroshi Nojima; Norikazu Yabuta
Journal:  Cell Cycle       Date:  2019-07-04       Impact factor: 4.534

8.  PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Authors:  Girija Dasmahapatra; Hiral Patel; Tri Nguyen; Elisa Attkisson; Steven Grant
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531

9.  Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.

Authors:  Xianzeng Hou; Zhiguo Li; Weize Huang; Jiejie Li; Christopher Staiger; Shihuan Kuang; Tim Ratliff; Xiaoqi Liu
Journal:  Prostate       Date:  2013-05-09       Impact factor: 4.104

10.  Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma.

Authors:  Ping Chen; Xia Zhao; Liang Ma
Journal:  Mol Cell Biochem       Date:  2013-07-11       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.